Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Somatostatin analog (oral)

Mycapssa (octreotide (oral capsules))

An approved treatment for Acromegaly.

FDA Approved (2020)by Chiesi (originally Chiasma)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2020

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Octreotide (oral capsules) wherever you encounter it, plus the key facts at a glance.

Generic name
Octreotide (oral capsules)
Brand name
Mycapssa
Development codes
oral octreotide capsules, OOC
Drug class
Somatostatin analog (oral)
Manufacturer
Chiesi (originally Chiasma)
How it's taken
Taken by mouth as 20mg capsules on an empty stomach, at least 1 hour before or 2 hours after a meal, twice daily.

The first oral somatostatin analog for acromegaly, a capsule form of octreotide, the same medicine long given by injection.

FDA-approved in June 2020 for long-term maintenance in people with acromegaly who have already responded to and tolerated injectable octreotide or lanreotide, it lets suitable patients control the disease with a pill instead of regular injections.

Follow Mycapssa by email

We'll email you when Mycapssa's FDA label changes, when the FDA acts on it, and when new trials for Acromegaly open. Unsubscribe anytime.

You'll get, for Acromegaly:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Octreotide (oral capsules) fits

Mycapssa is a maintenance option for people with acromegaly already controlled on an injectable somatostatin analog (octreotide or lanreotide) who would prefer a capsule to long-acting injections.

  • The FDA approval covers only people who have already responded to and tolerated the injectable forms, so Mycapssa is not a starting treatment.
  • Palsonify (paltusotine), a once-daily tablet approved in September 2025, is another oral option, approved for adults whose acromegaly was not controlled by surgery or who cannot have surgery.
  • Whether either pill fits is a question to bring to an endocrinologist.

How Octreotide (oral capsules) works

In acromegaly, a benign pituitary tumor pumps out too much growth hormone (GH), which in turn drives up a second hormone called IGF-1 and causes the disease's bone, tissue, and metabolic changes. Octreotide is a lab-made copy of somatostatin, the body's natural 'off switch' for GH. It binds somatostatin receptors (mainly subtypes 2 and 5) on the tumor cells and tells them to stop releasing GH, which lowers IGF-1.

Octreotide has been used as an injection for decades. The hard part was making it work as a pill, because peptides like octreotide are normally destroyed in the gut and are too large to absorb. Mycapssa solves this with a Transient Permeability Enhancer (TPE), an oily suspension that briefly and reversibly loosens the junctions between intestinal cells so a portion of the drug can pass into the bloodstream[1].

Side effects and safety

What patients report

Because it is the same molecule as injectable octreotide, the side effects are similar. In the placebo-controlled trial, diarrhea (29% vs 21% on placebo) and nausea (21% vs 11%) were the most common. Stomach side effects were mostly mild to moderate, came in the first 3 months and cleared in a median of 8 days. In the longer open-label study, headache (33%), nausea (30%) and joint pain (26%) led the list.

Longer-term somatostatin-analog use is associated with gallstones (cholelithiasis), so doctors may monitor the gallbladder. Octreotide can also affect blood sugar (raising or lowering it) and slow the heart rate, so blood sugar and thyroid function are checked from time to time, and doses of heart-rate-lowering drugs such as beta blockers may need adjusting[7].

The label also warns about fatty, loose stools from poor fat absorption and about changes in vitamin B12 levels, so B12 is checked during treatment. The label says Mycapssa should not be used by anyone allergic to octreotide or any ingredient in the capsules, since anaphylactic reactions have been reported with octreotide[7].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Octreotide (oral capsules)

Taken by mouth as 20mg capsules on an empty stomach, at least 1 hour before or 2 hours after a meal, twice daily. The typical starting dose is 40mg per day (20mg in the morning and 20mg in the evening), and the dose can be titrated up to a maximum of 80mg per day based on IGF-1 levels and symptoms, and people with end-stage kidney disease start at 20mg once a day.

Swallow the capsules whole with a glass of water. Heartburn and acid medicines, such as proton pump inhibitors like omeprazole, H2 blockers and antacids, can lower how much Mycapssa you absorb, so a higher dose may be needed. Mycapssa can also make combined birth control pills less effective, so the label advises a non-hormonal or backup method[7].

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Mycapssa

With private insurance, the drugmaker's copay card can lower what you pay for Mycapssa. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 3 charity funds for Acromegaly, 1 was open on November 16, 2026. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Mycapssa (Octreotide (oral capsules))
  • Copay help

    Mycapssa Copay Program: eligible commercially insured patients may pay as little as $0. Government-funded plans are not eligible.

    For: private insurance · source
  • Insurance and case manager help

    Team helps with prior authorization, insurance approval and appeals; pharmacists and patient education support.

    The official page does not say who qualifies. Ask the program. · source

Good to know: Offered through PANTHERx Rare Pharmacy. Uninsured patients may qualify for more help through a Patient Assistance Program judged on household size and income; the page does not publish the income limits.

Checked on the drugmaker's official pages on November 3, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Acromegaly

  • From a charity · TotalAssist (formerly PAN Foundation)
    Acromegaly fund
    Open

    Pays for: Out-of-pocket costs for approved medications, up to $5,000 per year. Requires Medicare, Medicaid or TRICARE.

  • From a charity · The Assistance Fund
    Acromegaly fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.

Every program and charity fund for Acromegaly →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

How acromegaly treatments compare

This chart compares 6 of the medicines the FDA has approved for acromegaly. Your endocrinologist will recommend a treatment based on your tumor size, IGF-1 levels, symptoms, and how you respond to initial therapy. This chart summarizes the key practical differences between options.

Acromegaly has 6 FDA-approved treatments: Sandostatin LAR (octreotide, approved 1998); Somatuline Depot (lanreotide, approved 2007); Signifor LAR (pasireotide, approved 2014); Somavert (pegvisomant, approved 2003); Palsonify (paltusotine, approved 2025); Mycapssa (octreotide (oral capsules), approved 2020). Sandostatin LAR is typically used as first-line medical therapy (injectable).

DrugHow it worksHow it’s givenHow oftenWhere you get itTypical useFDA approved
Sandostatin LAR
octreotide
Somatostatin analog, mimics a hormone that tells the pituitary to release less growth hormoneIntramuscular injection (gluteal muscle)Every 4 weeksClinic or infusion centerFirst-line medical therapy (injectable)1998
Somatostatin analog, same receptor target as octreotide, but given as a deep subcutaneous gel rather than an intramuscular injectionDeep subcutaneous injection (upper outer buttock)Every 4 weeks (FDA-approved extended dosing: 120mg every 6 or 8 weeks for patients controlled on 60 or 90mg)Clinic (healthcare provider administration per FDA label)First-line medical therapy (injectable)2007
Signifor LAR
pasireotide
Multi-receptor somatostatin analog, targets more receptor subtypes than first-generation optionsIntramuscular injection (gluteal muscle)Every 4 weeksClinic or infusion centerOften used after octreotide or lanreotide, though the label does not require them first2014
Somavert
pegvisomant
Growth hormone receptor antagonist, blocks GH from binding to cells instead of reducing GH releaseSubcutaneous injection (self-administered)DailyHome (self-injection)Often used when somatostatin analogs are not enough; adding it to one is off-label2003
Palsonify
paltusotine
Oral somatostatin agonist, activates the same SST2 receptor as injectable somatostatin analogs, taken as a pillOral tabletOnce dailyHome (oral, no injection needed)First-line medical therapy, or switch from injectable somatostatin analog2025
Mycapssa
octreotide (oral capsules)
You are here
Somatostatin analog, the same medicine as Sandostatin LAR in a capsuleOral capsuleTwice dailyHome (oral, no injection needed)Maintenance for people already controlled on octreotide or lanreotide shots2020
Sandostatin LAR
octreotide · Novartis
MechanismSomatostatin analog, mimics a hormone that tells the pituitary to release less growth hormone
RouteIntramuscular injection (gluteal muscle)
FrequencyEvery 4 weeks
WhereClinic or infusion center
Typical useFirst-line medical therapy (injectable)
Approved1998
Somatuline Depot
lanreotide · Ipsen
MechanismSomatostatin analog, same receptor target as octreotide, but given as a deep subcutaneous gel rather than an intramuscular injection
RouteDeep subcutaneous injection (upper outer buttock)
FrequencyEvery 4 weeks (FDA-approved extended dosing: 120mg every 6 or 8 weeks for patients controlled on 60 or 90mg)
WhereClinic (healthcare provider administration per FDA label)
Typical useFirst-line medical therapy (injectable)
Approved2007
Signifor LAR
pasireotide · Recordati
MechanismMulti-receptor somatostatin analog, targets more receptor subtypes than first-generation options
RouteIntramuscular injection (gluteal muscle)
FrequencyEvery 4 weeks
WhereClinic or infusion center
Typical useOften used after octreotide or lanreotide, though the label does not require them first
Approved2014
Somavert
pegvisomant · Pfizer
MechanismGrowth hormone receptor antagonist, blocks GH from binding to cells instead of reducing GH release
RouteSubcutaneous injection (self-administered)
FrequencyDaily
WhereHome (self-injection)
Typical useOften used when somatostatin analogs are not enough; adding it to one is off-label
Approved2003
Palsonify
paltusotine · Vertex (acquired Crinetics)
MechanismOral somatostatin agonist, activates the same SST2 receptor as injectable somatostatin analogs, taken as a pill
RouteOral tablet
FrequencyOnce daily
WhereHome (oral, no injection needed)
Typical useFirst-line medical therapy, or switch from injectable somatostatin analog
Approved2025
MycapssaThis drug
octreotide (oral capsules) · Chiesi
MechanismSomatostatin analog, the same medicine as Sandostatin LAR in a capsule
RouteOral capsule
FrequencyTwice daily
WhereHome (oral, no injection needed)
Typical useMaintenance for people already controlled on octreotide or lanreotide shots
Approved2020

This chart summarizes approved acromegaly treatments to help you compare your options. It is not medical advice. Treatment decisions depend on your individual health profile, tumor characteristics, lab results, and response to therapy. Dosing intervals shown reflect FDA labeling; your endocrinologist may adjust intervals based on your individual response. Always discuss options with your endocrinologist.

Clinical trial results

FDA approval in June 2020 was based on the Phase 3 CHIASMA OPTIMAL trial, a randomized, double-blind, placebo-controlled study in adults with acromegaly already controlled on injectable somatostatin analogs. Among 56 patients in the 9-month trial (NCT03252353), 58% of those switched to the capsules kept a normal IGF-1, compared with 19% of those switched to placebo, and 25% on the capsules needed to go back to injections at some point[7].

A second Phase 3 study, MPOWERED, compared oral octreotide capsules against continued injectable somatostatin-analog therapy and found the oral capsules maintained biochemical response with a safety profile consistent with the injectable drugs, supporting long-term maintenance use. In that trial, 50 of 55 people (91%) who stayed on the capsules kept their response, compared with 37 of 37 (100%) on injections, which met the trial's preset noninferiority margin[8].

Development history

Oral octreotide was developed by Chiasma using its Transient Permeability Enhancer (TPE) technology to overcome the long-standing problem of delivering a peptide by mouth. After an initial FDA Complete Response Letter in 2016, Chiasma generated additional data and won FDA approval for Mycapssa on June 26, 2020, the first oral somatostatin analog[1].

Amryt Pharma completed its acquisition of Chiasma in August 2021[3], and Chiesi completed its acquisition of Amryt in April 2023[4]. Mycapssa is now sold in the US by Chiesi USA[7].

Ask anything about Octreotide (oral capsules)
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Acromegaly trials

Other Acromegaly treatments

Common questions about Octreotide (oral capsules)

▸What is Octreotide (oral capsules) (Mycapssa)?

The first oral somatostatin analog for acromegaly, a capsule form of octreotide, the same medicine long given by injection. FDA-approved in June 2020 for long-term maintenance in people with acromegaly who have already responded to and tolerated injectable octreotide or lanreotide, it lets suitable patients control the disease with a pill instead of regular injections.

▸How does Octreotide (oral capsules) work?

In acromegaly, a benign pituitary tumor pumps out too much growth hormone (GH), which in turn drives up a second hormone called IGF-1 and causes the disease's bone, tissue, and metabolic changes. Octreotide is a lab-made copy of somatostatin, the body's natural 'off switch' for GH. It binds somatostatin receptors (mainly subtypes 2 and 5) on the tumor cells and tells them to stop releasing GH, which lowers IGF-1.

Octreotide has been used as an injection for decades. The hard part was making it work as a pill, because peptides like octreotide are normally destroyed in the gut and are too large to absorb. Mycapssa solves this with a Transient Permeability Enhancer (TPE), an oily suspension that briefly and reversibly loosens the junctions between intestinal cells so a portion of the drug can pass into the bloodstream[1].

▸What are the side effects of Octreotide (oral capsules)?

Because it is the same molecule as injectable octreotide, the side effects are similar. In the placebo-controlled trial, diarrhea (29% vs 21% on placebo) and nausea (21% vs 11%) were the most common. Stomach side effects were mostly mild to moderate, came in the first 3 months and cleared in a median of 8 days. In the longer open-label study, headache (33%), nausea (30%) and joint pain (26%) led the list. Longer-term somatostatin-analog use is associated with gallstones (cholelithiasis), so doctors may monitor the gallbladder. Octreotide can also affect blood sugar (raising or lowering it) and slow the heart rate, so blood sugar and thyroid function are checked from time to time, and doses of heart-rate-lowering drugs such as beta blockers may need adjusting[7]. The label also warns about fatty, loose stools from poor fat absorption and about changes in vitamin B12 levels, so B12 is checked during treatment. The label says Mycapssa should not be used by anyone allergic to octreotide or any ingredient in the capsules, since anaphylactic reactions have been reported with octreotide[7].

▸How is Octreotide (oral capsules) taken?

Taken by mouth as 20mg capsules on an empty stomach, at least 1 hour before or 2 hours after a meal, twice daily. The typical starting dose is 40mg per day (20mg in the morning and 20mg in the evening), and the dose can be titrated up to a maximum of 80mg per day based on IGF-1 levels and symptoms, and people with end-stage kidney disease start at 20mg once a day. Swallow the capsules whole with a glass of water. Heartburn and acid medicines, such as proton pump inhibitors like omeprazole, H2 blockers and antacids, can lower how much Mycapssa you absorb, so a higher dose may be needed. Mycapssa can also make combined birth control pills less effective, so the label advises a non-hormonal or backup method[7].

▸Is Octreotide (oral capsules) FDA approved?

Yes, Octreotide (oral capsules) (Mycapssa) is FDA approved (2020) for the treatment of Acromegaly.

▸What is Mycapssa used for?

Mycapssa is an oral capsule form of octreotide and the first oral somatostatin analog for acromegaly. The FDA approved it on June 26, 2020 for long-term maintenance treatment in people with acromegaly who have already responded to and tolerated injectable octreotide or lanreotide, letting suitable patients control the disease with a pill instead of regular injections. Mycapssa is now sold in the US by Chiesi USA. [1][4]

▸How is Mycapssa taken?

Mycapssa is taken by mouth as 20mg capsules twice daily on an empty stomach, at least 1 hour before or 2 hours after a meal. The typical starting dose is 40mg per day (20mg in the morning and 20mg in the evening), and the dose can be increased to a maximum of 80mg per day based on IGF-1 levels and symptoms. Acid medicines can lower absorption, and Mycapssa can make combined birth control pills less effective. [7]

▸What are the side effects of Mycapssa?

Because Mycapssa is the same molecule as injectable octreotide, the side effects are similar. In the placebo-controlled trial, diarrhea (29% vs 21% on placebo) and nausea (21% vs 11%) were the most common, and stomach side effects mostly came in the first 3 months and cleared in a median of 8 days. In the longer open-label study, headache (33%), nausea (30%) and joint pain (26%) led the list. Longer-term somatostatin-analog use is associated with gallstones, so doctors may monitor the gallbladder. Octreotide can also raise or lower blood sugar and slow the heart rate, and the label warns about fatty, loose stools from poor fat absorption and about changes in vitamin B12 levels, so B12 is checked during treatment. [7]

▸What did the Mycapssa trials show?

FDA approval of Mycapssa in June 2020 was based on the Phase 3 CHIASMA OPTIMAL trial, a randomized, double-blind, placebo-controlled study in adults with acromegaly already controlled on injectable somatostatin analogs. Of those switched to the capsules, 58% kept a normal IGF-1, compared with 19% of those switched to placebo. A second Phase 3 study, MPOWERED, compared the capsules against continued injectable therapy and found they maintained biochemical response with a safety profile consistent with the injectable drugs. [7][8]

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Chiasma (GlobeNewswire) · June 2020. Chiasma Announces FDA Approval of MYCAPSSA (Octreotide) Capsules, the First and Only Oral Somatostatin Analog. https://www.globenewswire.com/news-release/2020/06/26/2054210/0/en/Chiasma-Announces-FDA-Approval-of-MYCAPSSA-Octreotide-Capsules-the-First-and-Only-Oral-Somatostatin-Analog.html
  2. U.S. Food and Drug Administration. Drugs@FDA: MYCAPSSA (octreotide) delayed-release capsules, NDA 208232. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208232
  3. Amryt Pharma (GlobeNewswire) · 2021-08-05. Amryt Successfully Completes Acquisition of Chiasma Inc. https://www.globenewswire.com/news-release/2021/08/05/2275818/0/en/Amryt-Successfully-Completes-Acquisition-of-Chiasma-Inc-Board-Appointments-Issues-Ordinary-Shares-and-Total-Voting-Rights.html
  4. Chiesi Farmaceutici (PR Newswire, via BioSpace) · 2023-04-12. Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc. https://www.biospace.com/chiesi-farmaceutici-s-p-a-completes-acquisition-of-amryt-pharma-plc
  5. Chiesi USA (Mycapssa.com). MYCAPSSA (octreotide) delayed-release capsules, Dosing and Administration. https://www.mycapssa.com/hcp/dosing
  6. European Journal of Endocrinology (PMC). Durable biochemical response and safety with oral octreotide capsules in acromegaly. https://pmc.ncbi.nlm.nih.gov/articles/PMC9641789/
  7. U.S. National Library of Medicine (DailyMed) · July 2025. MYCAPSSA (octreotide) delayed-release capsules, prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d80bc6-bdfb-4908-93e7-aace447c8d1a
  8. The Lancet Diabetes & Endocrinology · February 2022. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. https://pubmed.ncbi.nlm.nih.gov/34953531/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Mycapssa by email

We'll email you when Mycapssa's FDA label changes, when the FDA acts on it, and when new trials for Acromegaly open. Unsubscribe anytime.

You'll get, for Acromegaly:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site